A detailed history of Jane Street Group, LLC transactions in Elevation Oncology, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 29,668 shares of ELEV stock, worth $15,724. This represents 0.0% of its overall portfolio holdings.

Number of Shares
29,668
Previous 50,120 40.81%
Holding current value
$15,724
Previous $135,000 87.41%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.56 - $3.02 $11,453 - $61,765
-20,452 Reduced 40.81%
29,668 $17,000
Q2 2024

Aug 14, 2024

SELL
$2.35 - $5.17 $67,633 - $148,792
-28,780 Reduced 36.48%
50,120 $135,000
Q1 2024

May 15, 2024

BUY
$0.59 - $5.13 $46,551 - $404,757
78,900 New
78,900 $404,000
Q1 2023

May 15, 2023

BUY
$0.75 - $2.55 $7,836 - $26,644
10,449 New
10,449 $19,000
Q1 2022

May 17, 2022

SELL
$2.34 - $6.41 $48,887 - $133,917
-20,892 Closed
0 $0
Q4 2021

Feb 15, 2022

BUY
$4.15 - $8.86 $86,701 - $185,103
20,892 New
20,892 $126,000

Others Institutions Holding ELEV

About Elevation Oncology, Inc.


  • Ticker ELEV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 23,300,900
  • Market Cap $12.3M
  • Description
  • Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced sol...
More about ELEV
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.